Table 4.

Combination index values for the apoptotic effects of doxorubicin and Nutlin-3a

	Sequence*	ED50	ED75	ED90	ED95	Averaged CI†
OCI-AML-3
Sample 1	DOX + 3a	0.76	0.67	0.60	0.55	0.65
Sample 2	DOX →3a	0.89	0.84	0.80	0.79	0.83
Sample 3	3a → DOX	0.81	0.82	0.83	0.84	0.83
MOLM-13
Sample 1	DOX + 3a	0.91	0.57	0.39	0.32	0.55
Sample 2	DOX → 3a	0.80	0.73	0.66	0.62	0.70
Sample 3	3a → DOX	0.75	0.60	0.48	0.42	0.56
Primary AML
No. 1	DOX + 3a	0.84	0.81	0.80	0.79	0.81
No. 2	DOX + 3a	0.85	0.83	0.81	0.80	0.82
Normal CD34+
No. 1	DOX + 3a	1.10	1.18	1.26	1.32	1.22
No. 2	DOX + 3a	1.46	1.27	1.13	1.05	1.23
No. 3	DOX + 3a	0.76	0.90	1.10	1.27	1.01

^*Doxorubicin (DOX) and Nutlin-3a (3a) were administered simultaneously (DOX+3a) or sequentially with a 24-hour interval (DOX→3a or 3a→DOX).

^†The averaged combination index (CI) values were calculated from the ED₅₀, Ed₇₅, ED₉₀, and ED₉₅.